Abstract
The therapeutic outcomes for craniofacial surgery for malignant tumors involving the anterior skull base have remained relatively stationary for the past 30 years. Overall survival remains around 60% at 5 years and complications occur in approximately 30 to 35% of patients, although operative mortality remains under 5%. Improvement in therapeutic outcomes can be addressed under three headings: (1) reduction in morbidity and mortality of craniofacial surgery; (2) improvement in locoregional control, which is the most common manifestation of treatment failure; (3) improvement in overall and disease-free survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
